• Saniona plans to file an Investigational New Drug (IND) application with the US FDA for SAN2465 by end-October 2026, clearing the path for first-in-human testing.
• The company is preparing a Phase 1 trial in healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.